Lack of hemodynamic response to long-acting octreotide (Sandostatin LAR) in patients with cirrhosis

Lock of Hemodynamic Response to Long-Acting Octreotide (Sandostatin LAR) in Patients with Cirrhosis P S. Kamath, Mayo CUn, Rochester, MN; K ~nner, OHSU, Portland, OR; A Blei, Northwestern Memorial Hosp, Chicago, IL; J Bosch, Hosp Clin I Provincial, Barcelona Spain; W Carey, Cleveland Clin, Cleveland, OH; N Grace, Faulkner Hosp, Jamaica Plain, MA; K Kowdley, Univ of Washington, Seattle, WA; K Sizer, Novartis Pharmaceuticals Corp, East Hanover, NJ; R Groszmann, VA Medical Ctr, West Haven, VA